Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a trailing P/E of 45.2, forward P/E of 22.1. Trailing earnings yield is 2.21%, forward earnings yield 4.52%. Graham Number is $11.43.
Criteria proven by this page:
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.5 | 0.34 | 4.69 | 2,831.10 | - |
| 2017 | -9.2 | 0.14 | 3.89 | 10.08 | - |
| 2018 | -29.5 | -0.77 | 16.77 | 99.53 | - |
| 2019 | 38.9 | -0.18 | 10.81 | 15.67 | - |
| 2020 | -51.3 | 0.24 | 9.39 | 49.29 | - |
| 2021 | -46.0 | -0.74 | 15.84 | 46.84 | - |
| 2022 | -19.8 | -0.87 | 8.74 | 14.33 | - |
| 2023 | -14.0 | -0.98 | 10.63 | 11.98 | - |
| 2024 | -3.9 | -0.02 | 12.51 | 653.40 | - |
| 2025 | -2,828.5 | 28.35 | 9.90 | 5.56 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.34 | $158.33K | $-81.72M | -51614.6% |
| 2017 | $-0.47 | $31.41M | $-34.38M | -109.5% |
| 2018 | $-0.65 | $16.14M | $-54.45M | -337.3% |
| 2019 | $0.69 | $168.8M | $67.97M | 40.3% |
| 2020 | $-0.84 | $87.99M | $-84.55M | -96.1% |
| 2021 | $-1.36 | $138.29M | $-140.85M | -101.9% |
| 2022 | $-1.67 | $243.23M | $-176.49M | -72.6% |
| 2023 | $-1.92 | $240.74M | $-205.28M | -85.3% |
| 2024 | $-5.00 | $355.1M | $-599.49M | -168.8% |
| 2025 | $-0.01 | $829.45M | $-1.63M | -0.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.21 | $-4.22 – $-1.74 | $454.26M | $358.26M – $614.11M | 11 |
| 2027 | $-4.08 | $-5.87 – $-1.85 | $317.75M | $162.89M – $447.04M | 9 |
| 2028 | $-2.81 | $-4.10 – $-1.10 | $548.6M | $523.92M – $573.28M | 7 |
| 2029 | $-1.27 | $-1.96 – $-0.64 | $886.47M | $548.62M – $1.26B | 2 |
| 2030 | $3.01 | $1.52 – $4.65 | $1.62B | $1B – $2.3B | 5 |
